Tuya Pal, MD, is a Professor of Medicine in the Division of Genetic Medicine, Department of Medicine, and an Ingram Professor of Cancer Research at Vanderbilt University Medical Center, where she is also the Associate Director for Cancer Health Disparities at the Vanderbilt Ingram Cancer Center. She is a board-certified practicing clinical cancer geneticist focused on evaluation and management of patients with or at risk for inherited cancer. She is also the Vice Chair of the National Comprehensive Cancer Network Genetics/Familial Guidelines Committee for Breast, Ovarian and Pancreatic Cancer; as well as the Editor-in-Chief for the National Cancer Institute's Cancer Genetics PDQ Editorial Board. Dr. Pal is a physician scientist, with research focused on inherited cancer risks across basic and clinical services as well as health services delivery, including efforts in underserved populations. Dr. Pal founded the Inherited Cancer Registry (ICARE) Initiative over a decade ago, which is among the largest research registries focused on inherited cancers in the country. Through these efforts, she provides opportunities for education and engagement for patients and providers.

Dr. Deborah Cragun is an Associate Professor at the University of South Florida and the Founding Director of the only Genetic Counseling Graduate Program in the state of Florida. She earned her Master's degree in Medical Genetics from the University of Cincinnati and subsequently practiced as a genetic counselor in pediatric, prenatal, and cancer specialties. After earning a PhD in Public Health from the University of South Florida, she completed a postdoctoral research fellowship at Moffitt Cancer Center and has worked on grants from both the National Cancer Institute and National Human Genome Research Institute.

Marleah Dean Kruzel is an Associate Professor at the University of South Florida and a Collaborator Member in the Health Outcomes & Behavior Program at the Moffitt Cancer Center. Dr. Dean Kruzel's research interests are cancer communication and the communication of genetic risk information. Most of her projects investigate how patients, families, and clinicians exchange information, manage uncertainty, and make decisions regarding issues of hereditary cancer in order to create communication tools to improve health outcomes and health experiences. She is an expert in and has personal experiences as a previvor—a term used to describe individuals with inherited gene mutations who have not been diagnosed with cancer. Dr. Dean Kruzel's research is and has been funded by the National Cancer Institute, American Cancer Society, the Centers for Disease Control and Prevention, and the Patient-Centered Outcomes Research Institute.